Analysis Of Risk Factors And Treatment For Bloodstream Infections Due To Carbapenem Resistant Acinetobacter Baumannii

Objective:To explore the risk factors and treatment of patients with Carbapenem resistant Acinetobacter baumannii(CRAB)bloodstream infection(BSI),provide help for clinical treatment and prevention.Methods:1.1.A total of 137 AB BSI patients in our hospital were collected from January 1,2014 to July 30,2019.According to drug susceptibility results,they were divided into Carbapenem resistant Acinetobacter baumannii(CRAB)group and Carbapenem susceptible Acinetobacter baumannii(CSAB)group,of which 97 cases were CRAB group and 40 cases were CSAB group,and its risk factors were analyzed retrospectively.2.97 CRAB BSI patients were divided into tigecycline group(34 cases)and non-tigecycline group(63 cases),The tigacycline group was further grouped according to the specific combination of antibiotics,and their clinical characteristics and prognosis were compared.Results:1.With septic shock,use glucocorticoid and gastrointestinal intubation,with hypoproteinemia,use hormone before diagnosis,and WBC count?12×10~9/L after 3 days of antibiotics were independent risk factors for CRAB bloodstream infection.2.The 28-day mortality rate in the CSAB group was 12.5%,while that in the CRAB group was 56.70%,significantly higher than that in the CSAB group(P<0.001).The 28-day mortality rate was 58.82%in the tegacycline group and 55.56%in the non-tegacycline group(P>0.05).Conclusions:1.CRAB bloodstream infection is harmful and has a poor prognosis.2.With septic shock,and use glucocorticoid and gastrointestinal intubation,with hypoproteinemia,use hormone before diagnosis,and WBC count?12×10~9/L after 3 days of antibiotic use indicate poor prognosis.Tegacycline did not significantly reduce 28-day mortality rate and improve prognosis.3.Comparing the 28-day mortality rate,the CRAB group was significantly higher than the control group.4.Tigecycline did not significantly reduce the 28-day mortality rate and improve prognosis,and more clinical studies are needed to confirm its rigor in the selection of treatment options.